切换至 "中华医学电子期刊资源库"

中华介入放射学电子杂志 ›› 2019, Vol. 07 ›› Issue (03) : 251 -254. doi: 10.3877/cma.j.issn.2095-5782.2019.03.016

所属专题: 文献

综述

布加综合征的介入治疗研究进展
史青苗1, 袁新1, 李娟1, 余祖江1,()   
  1. 1. 450052 河南郑州,郑州大学第一附属医院感染科
  • 收稿日期:2019-04-09 出版日期:2019-08-01
  • 通信作者: 余祖江
  • 基金资助:
    国家自然科学基金青年科学基金项目(81702927)

Research progress in interventional therapy for treatment of Budd-Chiari syndrome

Qingmiao Shi1, Xin Yuan1, Juan Li1, Zujiang Yu1,()   

  1. 1. Department of Infection Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
  • Received:2019-04-09 Published:2019-08-01
  • Corresponding author: Zujiang Yu
  • About author:
    Corresponding author: Yu Zujiang, Email:
引用本文:

史青苗, 袁新, 李娟, 余祖江. 布加综合征的介入治疗研究进展[J]. 中华介入放射学电子杂志, 2019, 07(03): 251-254.

Qingmiao Shi, Xin Yuan, Juan Li, Zujiang Yu. Research progress in interventional therapy for treatment of Budd-Chiari syndrome[J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2019, 07(03): 251-254.

布加综合征是一种罕见的多病因疾病,临床表现可无症状、慢性或暴发性,其治疗应根据患者的病情采取逐步治疗策略。近年来,血管腔内介入治疗技术得到快速发展,依靠其安全、微创等优势,已成为布加综合征的首选治疗方式,其中,经皮腔内血管成形术、血管内支架植入术和经颈静脉肝内门体分流术在布加综合征的治疗中发挥重要价值。文章主要围绕布加综合征的介入治疗研究进展进行综述。

Budd-Chiari syndrome (BCS) is an infrequent disease with multiple causes. Its clinical manifestations could be asymptomatic, chronic or fulminant. The treatment strategy for BCS should be taken step by step basing on the patient's condition. In recent years, endovascular interventional therapy technology has developed rapidly, relying on its advantages such as safe and minimally invasive, it has became the first treatment choice for BCS. Among them, percutaneous transluminal angioplasty (PTA) and endovascular stent implantation (ESI) and transjugular intrahepatic portosystemic shunt (TIPS) gradually play an important role in the treatment for BCS. This article will review the research progress of interventional therapy for BCS.

[1]
Martens P, Nevens F. Budd-Chiari syndrome[J]. United European Gastroenterol J,2015,3(6): 489-500.
[2]
Bansal V, Gupta P, Sinha S,et al. Budd-Chiari syndrome: imaging review[J]. Br J Radiol,2018,91(1092): 20180441.
[3]
Eapen CE, Velissaris D, Heydtmann M,et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome[J]. Gut,2006,55(6): 878-884.
[4]
Valla DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction[J]. Hepatol Int,2018,12(Suppl 1): 168-180.
[5]
马秀现,叶学祥,冯留顺,等.球囊扩张血管成形治疗布-加综合征[J].普外临床,1996,11(6): 339-340,324.
[6]
Cui YF, Fu YF, Li DC,et al. Percutaneous recanalization for hepatic vein-type Budd-Chiari syndrome: long-term patency and survival[J]. Hepatol Int,2016,10(2): 363-369.
[7]
项军,朱耀青,王岩,等.不同球囊导管治疗下腔静脉阻塞的回顾性分析[J].徐州医学院学报,2004,24(1): 22-25.
[8]
Ding PX, Zhang SJ, Li Z,et al. Long-term safety and outcome of percutaneous transhepatic venous balloon angioplasty for Budd-Chiari syndrome[J]. J Gastroenterol Hepatol,2016,31(1): 222-228.
[9]
张文耀,许伟,徐浩,等.大球囊扩张治疗肝静脉阻塞型布-加综合征临床研究[J].介入放射学杂志,2018,27(10): 932-935.
[10]
韩新巍,丁鹏绪,吴刚.布加综合征下腔静脉阻塞直径30mm大球囊扩张的可行性研究[J].介入放射学杂志,2008,17(4): 243-246.
[11]
Han GH, Qi XS, Zhang W,et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center[J]. Radiology,2013,266(2): 657-667.
[12]
祖茂衡,张庆桥,顾玉明,等.血管内支架在布-加综合征远期疗效再评价[J].当代医学(中国介入放射学),2008(3):206-208.
[13]
Sonavane AD, Amarapurkar DN, Rathod KR,et al. Long term survival of patients undergoing TIPS in budd-chiari syndrome[J]. J Clin Exp Hepatol,2019,9(1): 56-61.
[14]
Hidaka M, Eguchi S. Budd-Chiari syndrome: Focus on surgical treatment[J]. Hepatol Res,2017,47(2): 142-148.
[15]
Garcia-Pagán JC, Heydtmann M, Raffa S,et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients[J]. Gastroenterology,2008,135(3): 808-815.
[16]
He FL, Wang L, Zhao HW,et al. Transjugular intrahepatic portosystemic shunt for severe jaundice in patients with acute Budd-Chiari syndrome[J]. World J Gastroenterol,2015,21(8): 2413-2418.
[17]
Fitsiori K, Tsitskari M, Kelekis A,et al. Transjugular intrahepatic portosystemic shunt for the treatment of Budd-Chiari syndrome patients: results from a single center[J]. Cardiovasc Intervent Radiol,2014,37(3): 691-697.
[18]
顾玉明,祖茂衡,徐浩,等. 500例Budd-Chiari综合征介入治疗并发症分析[J].中华放射学杂志,2003,37(12): 1083-1086.
[19]
宋文,汪名权,张德志,等.布加综合征介入治疗中并发心包填塞、下腔静脉破裂规避策略[J].肝胆外科杂志,2016,24(4): 270-272.
[20]
祖茂衡,徐浩,顾玉明,等.布加综合征疑难病例与介入治疗相关并发症的处理(附1859例报道)[J].中国普外基础与临床杂志,2014,21(12): 1487-1494.
[21]
陈汉威,黄晨,黄益,等.静脉微创介入治疗进展[J].中华介入放射学电子杂志,2017,5(2): 61-64.
[1] 刘虹宏, 杨永红, 张冬花, 林运. 老年冠脉分叉病变主支支架植入后在损伤边支使用药物涂层球囊进行修复的临床研究[J]. 中华损伤与修复杂志(电子版), 2023, 18(05): 387-393.
[2] 张龙飞, 高涌, 张懿刚, 余朝文, 刘德朗, 刘亚, 陈世远. 载脂蛋白B、性激素结合球蛋白及金属蛋白酶组织抑制剂-1在皖北地区原发性下腔静脉隔膜型布加综合征的临床意义[J]. 中华普通外科学文献(电子版), 2023, 17(04): 252-256.
[3] 樊逸隽, 杨枫, 王玮, 殷鹤英, 刘俊. 喉前淋巴结转移对甲状腺乳头状癌诊疗价值的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(04): 306-310.
[4] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[5] 张海涛, 康婵娟, 翟静洁. 胰管支架置入治疗急性胆源性胰腺炎效果观察[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 654-657.
[6] 钟文文, 李科, 刘碧好, 蔡炳, 脱颖, 叶雷, 马波, 瞿虎, 汪中扬, 王德娟, 邱剑光. 不同比例聚乳酸/丝素蛋白复合支架在兔尿道缺损修复中的疗效[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(05): 516-522.
[7] 张林, 刘芳, 赵静, 刘勇, 周青. 远程康复在慢性阻塞性肺疾病患者肺康复中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 601-604.
[8] 魏小勇. 原发性肝癌转化治疗焦点问题探讨[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 602-607.
[9] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[10] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[11] 蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[12] 吴一菡, 雷章, 卢宏达. MUC16/CA125在良恶性肿瘤诊治中的作用及其研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(05): 591-595.
[13] 李世凯, 梁佳, 何艳艳, 于毅, 李天晓, 常金龙, 贺迎坤. 兔颈动脉粥样硬化性狭窄模型在介入治疗的应用进展[J]. 中华介入放射学电子杂志, 2023, 11(04): 357-362.
[14] 吴佳霖, 罗骏阳, 钟胜, 王有枝, 姜在波. 肝内小直径覆膜支架联合抽栓、溶栓治疗门静脉血栓二例[J]. 中华介入放射学电子杂志, 2023, 11(04): 377-379.
[15] 张德伟, 雷毅, 江哲宇, 王黎洲, 许国辉, 周石. 杂交手术治疗下肢深静脉血栓合并下肢急性动脉血栓一例[J]. 中华介入放射学电子杂志, 2023, 11(04): 380-384.
阅读次数
全文


摘要